Bruyère Olivier, Detilleux Johann, Reginster Jean-Yves
Division of Public Health, Epidemiology and Health Economics, WHO Collaborating Centre for Epidemiology of Musculoskeletal Health and Ageing, University of Liège, 4000 Liège, Belgium.
Department of Physical Medicine and Rehabilitation, CHU Liège, 4000 Liège, Belgium.
Medicines (Basel). 2023 Mar 8;10(3):23. doi: 10.3390/medicines10030023.
The aim of this study was to evaluate the cost-effectiveness of different glucosamine formulations and preparations used for the management of osteoarthritis in Thailand compared with placebo.
We used a validated model to simulate the individual patient Utility score from aggregated data available from 10 different clinical trials. We then used the Utility score to calculate the quality-adjusted life year (QALY) over 3 and 6 months treatment period. We used the public costs of glucosamine products available in Thailand in 2019 to calculate the incremental cost-effectiveness ratio. We separated the analyses for prescription-grade crystalline glucosamine sulfate (pCGS) and other formulations of glucosamine. A cost-effectiveness cut-off of 3.260 USD/QALY was considered.
Irrespective of the glucosamine preparation (tablet or powder/capsule), the data show that pCGS is cost-effective compared with placebo over a 3 and 6 months. However, the other glucosamine formulations (e.g., glucosamine hydrochloride) never reached the breakeven point at any time.
Our data show that pCGS is cost-effective for the management of osteoarthritis in the Thai context while other glucosamine formulations are not.
本研究旨在评估在泰国用于治疗骨关节炎的不同氨基葡萄糖制剂和剂型与安慰剂相比的成本效益。
我们使用一个经过验证的模型，根据来自10项不同临床试验的汇总数据模拟个体患者效用评分。然后，我们使用该效用评分计算3个月和6个月治疗期内的质量调整生命年（QALY）。我们利用2019年泰国氨基葡萄糖产品的公共成本来计算增量成本效益比。我们分别对处方级结晶硫酸氨基葡萄糖（pCGS）和其他氨基葡萄糖剂型进行了分析。成本效益临界值设定为3260美元/QALY。
无论氨基葡萄糖制剂是片剂还是粉剂/胶囊剂，数据表明，在3个月和6个月的治疗期内，与安慰剂相比，pCGS具有成本效益。然而，其他氨基葡萄糖剂型（如盐酸氨基葡萄糖）在任何时候都未达到盈亏平衡点。
我们的数据表明，在泰国背景下，pCGS对骨关节炎的治疗具有成本效益，而其他氨基葡萄糖剂型则不然。
